



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: M. Rigdon Lentz

Serial No.: 09/699,003

Art Unit: 3762

Filed: October 26, 2000

Examiner: P. Bianco

For: *METHOD AND COMPOSITIONS FOR TREATMENT OF CANCERS*

RECEIVED

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

OCT 14 2003

TECHNOLOGY CENTER R3700

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicant submits a Supplemental Information Disclosure Statement, including three (3) pages of Form PTO-1449 and copies of the eighteen (18) documents cited therein.

Enclosed is a check for \$180.00 representing the fee required under 37 C.F.R. §1.17(p) for an Information Disclosure Statement filed after a first Office Action on the merits under 37 C.F.R. §1.97(c). It is believed that no additional fees are required with this submission. However, should an additional fee be required, the Commissioner is hereby authorized to charge any fees to Deposit Account No. 50-1868.

U.S. Patents

| <u>Number</u> | <u>Issue Date</u> | <u>Patentee</u> | <u>Class/Subclass</u> |
|---------------|-------------------|---------------------|-----------------------|
| 5,980,887 | 11-09-1999 | Isner, et al. | 424/93.7 |
| 6,017,527 | 01-25-2000 | Maraskovsky, et al. | 424/93.71 |

10/09/2003 EFLORES 00000071 09699003

01

FC:1806 180.00 0P

ATLI #1241687 v1

1

LEN 101 CIP CON
077829/00009

U.S.S.N.: 09/699,003
Filed: October 26, 2003
INFORMATION DISCLOSURE STATEMENT

Foreign Documents

| <u>Number</u> | <u>Publication Date</u> | <u>Patentee</u> | <u>Country</u> |
|---------------|-------------------------|-----------------|----------------|
| WO 91/09967 | 07-11-1991 | Celltech Ltd. | PCT |
| WO 01/37873 | 05-31-2001 | Lentz | PCT |

Publications

ADERKA, et al., "Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients," *Cancer Res.* 51: 5602-5607 (1991).

AMIT, et al., "Three-dimensional structure of an antigen-antibody complex at 2.8 resolution," *Science* 233: 747-751 (1986).

CLACKSON, et al., "Making of antibody fragments using phage display libraries," *Nature* 352: 624-688 (1991).

DAUGHERTY, et al., "Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins," *Nucl. Acids Res.* 19: 2471-2476 (1991).

DIGEL, et al., "High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia," *J. Clin. Invest.* 89: 1690-1693 (1992).

ELSÄSSER-BEILE, et al., "Increased plasma concentrations for type I and II tumor necrosis factor receptors and IL-2 receptors in cancer patients," *Tumor Biol.* 15: 17-24 (1993).

EY, et al., "Isolation of pure IgG₁, IgG_{2a}, and IgG_{2b} immunoglobins from mouse serum using protein A-Sepharose," *Immunochemistry* 15:429-436 (1978).

KABAT, et al., eds., Sequences of Proteins of Immunological Interest, 4th ed., U.S Dept. Health & Human Services: Bethesda, MD (1987).

KESSLER, "Adsorptive plasma treatment: optimization of extracorporeal devices and systems," *Blood Purif.* 11: 150-157 (1993).

LENTZ, et al., "Low molecular weight protein apheresis and regression of breast cancer," *Jpn. J. Apheresis* 16(1): 107-114 (1997).

PANKA, et al., "Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies," *Proc. Natl. Acad. Sci. USA* 85: 3080-3084 (1988).

RUDIKOFF, et al., "Single amino acid substitution altering antigen-binding specificity," *Immunology* 79: 1979-1983 (1982).

U.S.S.N.: 09/699,003

Filed: October 26, 2003

INFORMATION DISCLOSURE STATEMENT


SELINSKY & HOWELL, "Soluble tumor necrosis factor receptor type I enhances tumor development and persistence *in vivo*," *Cell. Immunol.* 200: 81-87 (2000).

SELINSKY, "Dissertation: The role of soluble tumor necrosis factor type I in tumor survival," Colorado State University, Fort Collins, Colorado (1999).

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicant invites the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicant is of the opinion that hisr claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,



Patrea L. Pabst
Reg. No. 31,284

Dated: October 2, 2003

HOLLAND & KNIGHT LLP
One Atlantic Center
1201 West Peachtree Street, N.E.
Suite 2000
Atlanta, Georgia 30309-3400
404-817-8473
FAX 404-817-8588
www.hklaw.com

U.S.S.N.: 09/699,003

Filed: October 26, 2003

INFORMATION DISCLOSURE STATEMENT

Certificate of Mailing under 37 C.F.R. § 1.8(a)

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: October 2, 2003

Peggy Bailey
Peggy Bailey

1241687_v1